financingEvonetix extends Series B financing to US$54mBritish Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital. more ➔
financingGermany’s Curevac offers common sharesmRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering. more ➔
partnershipsChong Kun Dang Pharm licences Synaffix ADC platformSouth Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BV’s propietary ADC platform. more ➔
Wikipedia/Ceescamel Clinical trialsNew EU stakeholder platform to speed up clinical trialsA new platform is set to facilitate the exchange of information on the optimisation of the electronic reporting system CTIS. more ➔
Novel Food Ultra-processed foods increase risk for cancerBritish researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer. more ➔
partnershipLonza collaborates with Asher Biotherapeutics IncAsher Biotherapeutics Inc has expanded its manufacturing agreement with Lonza to include the manufacturing of AB248. more ➔
partnershipEvotec and Janssen team up in immunoncologyEvotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies. more ➔
pixabay.com/SD-PicturesClimate changeEvidence of deliberate climate damageA new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance. more ➔
financingRewind Therapeutics extends Series A financingWith Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding. more ➔
infectionNew polymer can stop biofilm formation British researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters more ➔
Wikipedia/Ceescamel 
pixabay.com/SD-Pictures
